PHARMACOLOGICAL EVIDENCE ON THE USE OF CANNABIDIOL IN THE TREATMENT OF PATIENTS WITH PARKINSON'S DISEASE: AN INTEGRATIVE REVIEW
Main Article Content
Abstract
This work presents an integrative review of the pharmacological evidence on the use of cannabidiol (CBD) in the treatment of Parkinson’s disease. The databases PubMed, SciELO, LILACS, BVSMS, and Google Scholar were searched, covering the period from 2021 to 2025. After applying inclusion and exclusion criteria, six studies composed the final sample, including randomized clinical trials, case reports, and observational studies. The results demonstrated that the use of CBD, either alone or in combination with tetrahydrocannabinol (THC), shows an acceptable safety profile, with mild adverse events such as drowsiness and dizziness. Therapeutic potential was mainly observed for non-motor symptoms of PD, such as sleep disturbances, anxiety, and depression, which positively impact quality of life. However, the effects on motor symptoms were modest and inconsistent, with some trials showing no significant difference compared to placebo. A case report described marked benefit with high doses of THC, contrasting with the modest results of controlled trials. The main limitations identified were small sample sizes, short follow-up periods, relevant placebo effects, heterogeneity in disease stages, and variation in doses used. Therefore, it is concluded that although promising, the findings do not yet support the routine use of cannabinoids in clinical practice for PD. Future research should prioritize larger and longer trials, assessment of optimal doses, subgroup analyses, and monitoring of drug interactions in order to consolidate the clinical applicability of CBD in this context.
Article Details
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
A Revista Arte, Ciência e Tecnologia oferece acesso livre imediato ao seu conteúdo, sem necessidade de cadastro, que é obrigatório apenas no caso de submissão de trabalho. Os autores permanecem detentores dos direitos autorais do artigo, possibilitando assim sua difusão em repositórios, páginas de blog ou outros suportes e favorecendo a divulgação do conhecimento. A revista tem o direito de primeira publicação e deve ser citada no caso de divulgação posterior em outros suportes.
A Revista Arte, Ciência e Tecnologia é uma revista de acesso aberto, distribuída nos termos da Licença de Atribuição Creative Commons Atribuição 4.0 Internacional (CC BY 4.0), que permite o uso irrestrito, distribuição e reprodução dos artigos em qualquer meio, desde que a edição original seja devidamente citada.